ACE2 and COVID-19: These clinical manifestations of PASC could be a result of viral invasion directly into the tissues possibly facilitated by its receptor angiotensin-converting enzyme 2 (ACE2) expression, immune system dysregulation, hyperinflammation and cytokine storm syndrome, immune-mediated multi-system damage, maladaptation of ACE2-related pathways, endothelial damage and microvascular injury, hypercoagulable states associated with COVID-19, critical care-associated sequelae or a combination of these (31, 32).